About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lung Cancer Clinical Trials in Ohio | 865 Studies

Clinical Trials Lung CancerOhio

Lung Cancer Clinical Trials in Ohio

Find 865 clinical trials for lung cancer near Ohio. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in Ohio

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 421-440 of 865 trials

TerminatedNivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune DiseaseThe purpose of this study is to explore the safety, tolerability and activity of Nivolumab, a PD-1 inhibitor, in cohorts of patients with autoimmune disease.NCT03656627·Chicago, Illinois and 8 others CompletedStudy to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)This is a 2 part study in patients with EGFRm+ non small cell lung cancer (NSCLC), whose disease has progressed on an EGFRm TKI, who are refractory or resistant to standard…NCT02157883·San Diego, California and 15 others

PreviousPage 22 of 44Next

Lung Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedErlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFRIn this research study erlotinib will be given to eligible participants whose lung cancer has been removed by surgery.NCT00567359·Stanford, California and 7 others

Active not recruitingTesting the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine TumorsThis phase I trial studies the side effects and best dose of berzosertib (M6620 \[VX-970\]) when given together with whole brain radiation therapy in treating patients with…NCT02589522·Duarte, California and 8 others

RecruitingA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC)…NCT07144280·Alabaster, Alabama and 430 others

TerminatedASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung CancerThe purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.NCT00662597·Mobile, Alabama and 247 others

TerminatedPhase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLCGTI-4711-101 is a Phase I/II study of the safety of GC4711, its effect on in-field tumor response and its potential to reduce radiation-related pulmonary injury due to SBRT for…NCT04476797·Greeley, Colorado and 9 others

Active not recruitingA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerThis is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447)…NCT05221840·San Diego, California and 201 others

CompletedRucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV…NCT03845296·Mobile, Alabama and 949 others

Active not recruitingA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected…NCT06077760·Anchorage, Alaska and 228 others

RecruitingStudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCThe purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy…NCT06162221·Gilbert, Arizona and 92 others

CompletedPhase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLCThe primary objective is to determine the progression free survival with pemetrexed, and gemcitabine plus bevacizumab as first-line chemotherapy in elderly patients with Stage…NCT00517595·Waterbury, Connecticut and 9 others

CompletedEarly Detection of Second Lung Cancer in Patients With Stage I Non-small Cell Lung CancerRATIONALE: Using new methods to examine sputum samples for the presence of cancer cells may detect lung cancer earlier.NCT00002667·Tampa, Florida and 4 others

Active not recruitingA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in…NCT05984277·Hot Springs, Arkansas and 246 others

TerminatedNGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) TrialThis is a multicenter screening protocol designed to identify patients with NSCLC who have tumor mutations in the KEAP1 or NRF2/NFE2L2 genes in order to determine potential…NCT04698681·Daphne, Alabama and 62 others

WithdrawnA Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung CancerA Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with IpilimumabNCT03048136·San Francisco, California and 16 others

CompletedTrial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to ErlotinibPreclinical data in lung cancer cell lines showed that EGFR mutation can potentially be a positive predictor for sensitivity to BKM120.NCT01487265·Fort Myers, Florida and 6 others

CompletedPhase 1/1b Study of MGCD516 in Patients With Advanced CancerMGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR…NCT02219711·Birmingham, Alabama and 42 others

Active not recruitingComparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung CancerRATIONALE: Wedge resection or segmentectomy may be less invasive types of surgery than lobectomy for non-small cell lung cancer and may have fewer side effects and improve…NCT00499330·Birmingham, Alabama and 385 others

Active not recruitingBasket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsThis trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this…NCT04579380·Phoenix, Arizona and 107 others

Other Conditions in Ohio

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma